Q32 Bio Inc (QTTB)

In May 2026, Q32 Bio reported its First Quarter 2026 financial results, provided a corporate update, reiterated a "Buy" rating by HC Wainwright, and issued a warning regarding regulatory compliance risks. In April 2026, Q32 Bio expanded its at-the-market offering and participated in the 25th Annual Needham Virtual Healthcare Conference. In March 2026, Q32 Bio reported its Fourth Quarter 2025 financial results, completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial, completed a $10.5 million registered direct offering, and sold ADX-097 to Akebia Therapeutics. In February 2026, Q32 Bio completed a $10.5 million registered direct offering of common stock and pre-funded warrants. In December 2025, the company completed the asset sale of ADX-097 to Akebia Therapeutics. The stock price of Q32 Bio has increased by 61.7% year-to-date in 2026 and by 223.08% from May 5, 2025, to May 4, 2026.

Information regarding demand seasonality for Q32 Bio, Inc.'s products and services is not directly available. Stock performance data suggests that January has historically shown the highest probability of positive returns for QTTB stock, while April has historically shown the lowest. This seasonality relates to stock performance and not necessarily to the demand for the company's therapeutic products.

Q32 Bio, Inc. is a clinical-stage biotechnology company focused on developing biologic therapeutics that target regulators of the adaptive immune system to re-balance immunity in patients with autoimmune and inflammatory diseases, particularly alopecia areata. Their lead product candidate is bempikibart (ADX-914), a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling. Bempikibart is currently in a Phase 2 program, including the SIGNAL-AA Phase 2a clinical trial for severe alopecia areata. The company previously sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics in December 2025.

Q32 Bio, Inc. is headquartered in Waltham, Massachusetts, United States. Its common stock is listed on the Nasdaq Capital Market in the US, as well as the Deutsche Boerse AG in Germany and the London Stock Exchange in the United Kingdom.

Q32 Bio has a consensus rating of "Moderate Buy" from analysts, with a consensus price target of $13.00, representing a potential upside of approximately 142.1% from its current price of $5.37. MarketBeat's MarketRank™ scored Q32 Bio higher than 88% of evaluated companies. A warning was issued on May 6, 2026, regarding regulatory compliance risks due to internal control challenges under Sarbanes-Oxley.

Q32 Bio Inc. has 55 institutional owners and shareholders holding a total of 8,078,882 shares. Major institutional owners include Orbimed Advisors Llc, Atlas Venture Life Science Advisors, LLC, Carlyle Group Inc., Acorn Capital Advisors, Llc, Vanguard Group Inc, Arch Venture Corp, Pfizer Inc, Sanofi, Opaleye Management Inc., and Geode Capital Management, Llc. Institutions hold 31.32% of the stock, while insiders hold 40.00%.